09:51 AM EST - Immunovaccine Inc. : Announced that safety data from a Phase 1 clinical study showed that its DepoVax™ prophylactic Respiratory Syncytial Virus vaccine candidate ("DPX-RSV") was well tolerated in the Phase 1 study's first 20 volunteers, of whom eight subjects received the DPX-RSV vaccine. Immunovaccine Inc.
shares T.IMV are trading up $0.03 at $0.76.
